| Literature DB >> 10599874 |
M Canesi1, A Antonini, C B Mariani, S Tesei, A L Zecchinelli, M Barichella, G Pezzoli.
Abstract
Patients with Parkinson's disease (n = 68) switched from pergolide or bromocriptine to ropinirole overnight (dose equivalence ratios 1:6 and 10:6, respectively). The activities of daily living score for the Unified Parkinson's Disease Rating Scale (UPDRS) was significantly improved 4 weeks after the bromocriptine-ropinirole switch. All other UPDRS scores, including that for the side-effect component, were not significantly different after either switch. Overnight switching may be a safe therapeutic approach that may reduce hospitalisation and related socio-economic costs.Entities:
Mesh：
Substances：
Year: 1999 PMID： 10599874 DOI： 10.1007/s007020050212
Source DB: PubMed Journal: J Neural Transm (Vienna) ISSN： 0300-9564 Impact factor: 3.575